Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment

Immunobiology

Volumn 216, Issue 1-2, 2011, Pages 12-23

  Richardt Pargmann, Denise ^a   Wechsler, Miriam ^a   Krieg, Arthur M ^a   Vollmer, Jörg ^a   Jurk, Marion ^a  

^a PFIZER INC   (United States)

Author keywords

Single stranded oligoribonucleotide (ORN); T cell activation; TLR

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; LIGAND; OLIGORIBONUCLEOTIDE; SINGLE STRANDED OLIGORIBONUCLEOTIDE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 LIGAND; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 8 LIGAND; TOLL LIKE RECEPTOR 9 LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CONTACT; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MALE; MITOSIS INHIBITION; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMIDAZOLES; INTERFERON-GAMMA; LIPOPEPTIDES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RECEPTOR CROSS-TALK; RECEPTORS, ANTIGEN, T-CELL; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 78649512886     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.03.011     Document Type: Article

References (74)

1. Abreu M.T., Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. J. Pediatr. 2004, 144:421-429.
2. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 2002, 32:1958-1968.
3. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
4. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
5. Bekeredjian-Ding I., Roth S.I., Gilles S., Giese T., Ablasser A., Hornung V., Endres S., Hartmann G. T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J. Immunol. 2006, 176:7438-7446.
6. Beutner K.R., Tyring S.K., Trofatter K.F., Douglas J.M., Spruance S., Owens M.L., Fox T.L., Hougham A.J., Schmitt K.A. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 1998, 42:789-794.
7. Beutner K.R., Wiley D.J., Douglas J.M., Tyring S.K., Fife K., Trofatter K., Stone K.M. Genital warts and their treatment. Clin. Infect. Dis. 1999, 28(Suppl. 1):S37-S56.
8. Caron G., Duluc D., Fremaux I., Jeannin P., David C., Gascan H., Delneste Y. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J. Immunol. 2005, 175:1551-1557.
9. Carter L., Fouser L.A., Jussif J., Fitz L., Deng B., Wood C.R., Collins M., Honjo T., Freeman G.J., Carreno B.M. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol. 2002, 32:634-643.
10. Chon S.Y., Hassanain H.H., Pine R., Gupta S.L. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J. Interferon Cytokine Res. 1995, 15:517-526.
11. Cong Y.P., Song S.S., Bhagat L., Pandey R.K., Yu D., Kandimalla E.R., Agrawal S. Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochem. Biophys. Res. Commun. 2003, 310:1133-1139.
12. Curtsinger J.M., Lins D.C., Mescher M.F. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J. Immunol. 1998, 160:3236-3243.
13. Dolganiuc A., Garcia C., Kodys K., Szabo G. Distinct toll-like receptor expression in monocytes and T cells in chronic HCV infection. World J. Gastroenterol. 2006, 12:1198-1204.
14. Erickson S., Sangfelt O., Castro J., Heyman M., Einhorn S., Grander D. Interferon-alpha inhibits proliferation in human T lymphocytes by abrogation of interleukin 2-induced changes in cell cycle-regulatory proteins. Cell Growth Differ. 1999, 10:575-582.
15. Forsbach A., Nemorin J., Völp K., Samulowitz U., Montino C., Müller C., Tluk S., Hamm S., Bauer S., Lipford G., Vollmer J. Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides 2007, 17(4):405-417.
16. Forsbach A., Nemorin J.G., Montino C., Muller C., Samulowitz U., Vicari A.P., Jurk M., Mutwiri G.K., Krieg A.M., Lipford G.B., Vollmer J. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 2008, 180:3729-3738.
17. Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 2002, 109:295-299.
18. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
19. Furset G., Floisand Y., Sioud M. Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology 2008, 123(2):263-271.
20. Gajewski T.F., Fitch F.W. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 1988, 140:4245-4252.
21. Gorden K.K., Qiu X.X., Binsfeld C.C., Vasilakos J.P., Alkan S.S. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and PolyT oligodeoxynucleotides. J. Immunol. 2006, 177:6584-6587.
22. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., Rothenfusser S., Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-A induction in plasmacytoid dendritic cells. Eur. J. Immunol. 2003, 33:1633-1641.
23. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 2000, 164:944-953.
24. Hassanain H.H., Chon S.Y., Gupta S.L. Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-gamma and -alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor. J. Biol. Chem. 1993, 268:5077-5084.
25. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., Dietrich H., Lipford G., Takeda K., Akira S., Wagner H., Bauer S. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 2003, 33:2987-2997.
26. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptors 7 and 8. Science 2004, 303:1526-1529.
27. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3:196-200.
28. Hewson C.A., Jardine A., Edwards M.R., Laza-Stanca V., Johnston S.L. Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J. Virol. 2005, 79:12273-12279.
29. Honda K., Yanai H., Takaoka A., Taniguchi T. Regulation of the type I IFN induction: a current view. Int. Immunol. 2005, 17:1367-1378.
30. Hopkins P.A., Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin. Exp. Immunol. 2005, 140:395-407.
31. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11:263-270.
32. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
33. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 2000, 164:3596-3599.
34. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
35. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3:499.
36. Jurk M., Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007, 21:387-401.
37. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 2007, 19(1):39-45.
38. Kadoya A., Tone S., Maeda H., Minatogawa Y., Kido R. Gene structure of human indoleamine 2,3-dioxygenase. Biochem. Biophys. Res. Commun. 1992, 189:530-536.
39. Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007, 19:24-32.
40. Kearney E.R., Pape K.A., Loh D.Y., Jenkins M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994, 1:327-339.
41. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5:471-484.
42. Krogsgaard M., Davis M.M. How T cells 'see' antigen. Nat. Immunol. 2005, 6:239-245.
43. Lagasse E., Weissman I.L. Flow cytometric identification of murine neutrophils and monocytes. J. Immunol. Methods 1996, 197:139-150.
44. Latchman D.S. How can we use our growing understanding of gene transcription to discover effective new medicines?. Curr. Opin. Biotechnol. 1997, 8:713-717.
45. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., Lien E., Nilsen N.J., Espevik T., Golenbock D.T. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004, 5:190-198.
46. Lee J., Chuang T.H., Redecke V., She L., Pitha P.M., Carson D.A., Raz E., Cottam H.B. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6646-6651.
47. Lopez-Gonzalez J.S., Avila-Moreno F., Prado-Garcia H., Aguilar-Cazares D., Mandoki J.J., Meneses-Flores M. Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-alpha. Clin. Immunol. 2007, 122:323-329.
48. Matsumoto M., Kikkawa S., Kohase M., Miyake K., Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 2002, 293:1364-1369.
49. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001, 1:135-145.
50. Meier A., Bagchi A., Sidhu H.K., Alter G., Suscovich T.J., Kavanagh D.G., Streeck H., Brockman M.A., LeGall S., Hellman J., Altfeld M. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 2008, 22:655-658.
51. Mellor A.L., Baban B., Chandler P.R., Manlapat A., Kahler D.J., Munn D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 2005, 175:5601-5605.
52. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., Marshall B., Chandler P., Antonia S.J., Burgess R., Slingluff C.L., Mellor A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297:1867-1870.
53. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
54. Murad Y.M., Clay T.M., Lyerly H.K., Morse M.A. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol. Ther. 2007, 7:1257-1266.
55. Niedergang F., Hemar A., Hewitt C.R., Owen M.J., Dautry-Varsat A., Alcover A. The Staphylococcus aureus enterotoxin B superantigen induces specific T cell receptor down-regulation by increasing its internalization. J. Biol. Chem. 1995, 270:12839-12845.
56. O'Neill L.A. TLRs: Professor Mechnikov, sit on your hat. Trends Immunol. 2004, 25:687-693.
57. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., Wang D.Y., Li Y., Wang H.Y., Wang R.F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
58. Pihlgren M., Dubois P.M., Tomkowiak M., Sjogren T., Marvel J. Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J. Exp. Med. 1996, 184:2141-2151.
59. Romerio F., Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. FASEB J. 2002, 16:1680-1682.
60. Sabroe I., Parker L.C., Wilson A.G., Whyte M.K., Dower S.K. Toll-like receptors: their role in allergy and non-allergic inflammatory disease. Clin. Exp. Allergy 2002, 32:984-989.
61. Schetter C., Vollmer J. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9. Curr. Opin. Drug Discov. Dev. 2004, 7:204-210.
62. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2001, 2:947-950.
63. Seth A., Stern L.J., Ottenhoff T.H., Engel I., Owen M.J., Lamb J.R., Klausner R.D., Wiley D.C. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature 1994, 369:324-327.
64. Simberg D., Weisman S., Talmon Y., Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:257-317.
65. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 2005, 348:1079-1090.
66. Smits E.L., Ponsaerts P., Berneman Z.N., Van Tendeloo V.F. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008, 13:859-875.
67. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21:335-376.
68. Ueta M., Hamuro J., Kiyono H., Kinoshita S. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem. Biophys. Res. Commun. 2005, 331:285-294.
69. Uhlmann E., Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Dev. 2003, 6:204-217.
70. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., Krieg A.M. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34:251-262.
71. Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 2002, 5:62-69.
72. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., Kedl R.M., Mattapallil J.J., Weiss W.R., Roederer M., Seder R.A. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 2006, 203:1249-1258.
73. Wingender G., Garbi N., Schumak B., Jungerkes F., Endl E., von Bubnoff D., Steitz J., Striegler J., Moldenhauer G., Tuting T., Heit A., Huster K.M., Takikawa O., Akira S., Busch D.H., Wagner H., Hammerling G.J., Knolle P.A., Limmer A. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 2006, 36(1):12-20.
74. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168:554-561.